No AccessJournal of UrologyAdult Urology1 Nov 2009Prostate Specific Antigen Best Practice Statement: 2009 Updateis companion ofProstate Specific Antigen Best Practice Statement: 2009 Update Kirsten L. Greene, Peter C. Albertsen, Richard J. Babaian, H. Ballentine Carter, Peter H. Gann, Misop Han, Deborah Ann Kuban, A. Oliver Sartor, Janet L. Stanford, Anthony Zietman, and Peter Carroll Kirsten L. GreeneKirsten L. Greene , Peter C. AlbertsenPeter C. Albertsen , Richard J. BabaianRichard J. Babaian , H. Ballentine CarterH. Ballentine Carter , Peter H. GannPeter H. Gann , Misop HanMisop Han , Deborah Ann KubanDeborah Ann Kuban , A. Oliver SartorA. Oliver Sartor , Janet L. StanfordJanet L. Stanford , Anthony ZietmanAnthony Zietman , and Peter CarrollPeter Carroll View All Author Informationhttps://doi.org/10.1016/j.juro.2009.07.093AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: We provide current information on the use of PSA testing for the evaluation of men at risk for prostate cancer, and the risks and benefits of early detection. Materials and Methods: The report is a summary of the American Urological Association PSA Best Practice Policy 2009. The summary statement is based on a review of the current professional literature, clinical experience and the expert opinions of a multispecialty panel. It is intended to serve as a resource for physicians, other health care professionals, and patients. It does not establish a fixed set of guidelines, define the legal standard of care or pre-empt physician judgment in individual cases. Results: There are two notable differences in the current policy. First, the age for obtaining a baseline PSA has been lowered to 40 years. Secondly, the current policy no longer recommends a single, threshold value of PSA, which should prompt prostate biopsy. Rather, the decision to proceed to prostate biopsy should be based primarily on PSA and DRE results, but should take into account multiple factors including free and total PSA, patient age, PSA velocity, PSA density, family history, ethnicity, prior biopsy history and comorbidities. Conclusions: Although recently published trials show different results regarding the impact of prostate cancer screening on mortality, both suggest that prostate cancer screening leads to overdetection and overtreatment of some patients. Therefore, men should be informed of the risks and benefits of prostate cancer screening before biopsy and the option of active surveillance in lieu of immediate treatment for certain men diagnosed with prostate cancer. References 1 : Screening and prostate-cancer mortality in a randomized European study. N Engl J Med2009; 360: 11320. Google Scholar 2 Ries LA, Melbert D, Krapcho M et al: SEER Cancer Statistics Review, 1975–2005. Bethesda: National Cancer Institute. http://seer.cancer.gov/csr/1975_2005/. Based on November 2007 SEER data submission posted to the SEER web site 2008. Google Scholar 3 : Quantifying the role of PSA screening in the US prostate cancer mortality decline. Cancer Causes Control2008; 19: 175. Google Scholar 4 : Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: a surveillance modeling approach. Med Decis Making2003; 28: 323. Google Scholar 5 : Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med2005; 352: 1977. Google Scholar 6 : Survival associated with treatment vs. observation of localized prostate cancer in elderly men. JAMA2006; 296: 2683. Google Scholar 7 : Mortality results from a randomized prostate-cancer screening trial. N Engl J Med2009; 360: 1310. Google Scholar 8 : Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med1999; 341: 1781. Crossref, Medline, Google Scholar 9 : Pathological and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA1994; 271: 368. Google Scholar 10 : Preoperative prediction of small volume cancer (less than 0.5 ml) in radical prostatectomy specimens. J Urol2005; 174: 898. Link, Google Scholar 11 : Validation of the contemporary Epstein criteria for insignificant prostate cancer in European men. Eur Urol2008; 54: 1306. Google Scholar 12 : Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med2004; 351: 125. Google Scholar 13 : Screening for prostate cancer without digital rectal examination and transrectal ultrasound: results after four years in the European Randomized Study of Screening for Prostate Cancer (ERSPC), Rotterdam. Prostate2006; 66: 625. Google Scholar 14 : Prostate-specific antigen in hemodialysis patients and the influence of dialysis in its levels. Nephron2002; 90: 230. Google Scholar 15 : Intermethod differences in results for total PSA, free PSA, and percentage of free PSA. Am J Clin Pathol2008; 129: 952. Google Scholar 16 : Is prostate-specific antigen velocity useful in early detection of prostate cancer?: A critical appraisal of the evidence. J Natl Cancer Inst2007; 99: 1510. Google Scholar 17 : Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/mL or lower. JAMA2005; 294: 66. Google Scholar 18 : Serum prostate-specific antigen in a community-based population of healthy men: Establishment of age-specific reference ranges. JAMA1993; 270: 860. Crossref, Medline, Google Scholar 19 : Longitudinal evaluation of prostate specific antigen levels in men with and without prostate disease. JAMA1992; 267: 2215. Google Scholar 20 : Age adjusted prostate specific antigen and prostate specific antigen velocity cut points in prostate cancer screening. J Urol2007; 177: 499. Link, Google Scholar 21 : Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst2006; 98: 1521. Google Scholar 22 : Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. J Clin Oncol2009; 27: 398. Google Scholar 23 : Current age and race adjusted prostate specific antigen threshold values delay diagnosis of high grade prostate cancer. J Urol2007; 178: 1929. Link, Google Scholar 24 : Is the utility of prostate-specific antigen velocity for prostate cancer detection affected by age?. BJU Int2008; 101: 817. Google Scholar 25 : Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic diseases. JAMA1998; 279: 1542. Google Scholar 26 : Complexed prostate-specific antigen, complexed prostate-specific antigen density of total and transition zone, complexed/total prostate-specific antigen ratio, free-to-total prostate-specific antigen ratio, density of total and transition zone prostate-specific antigen: results of the prospective multicenter European trial. Urology2002; 60: 4. Google Scholar 27 : Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med2004; 350: 2239. Google Scholar 28 : Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old. Urology2006; 67: 316. Google Scholar 29 : Age-specific reference ranges for prostate-specific antigen in black men. N Engl J Med1996; 335: 304. Google Scholar 30 : Further analyses from the REDUCE prostate cancer risk reduction trial. J Urol, suppl2009; 181: 555. abstract LBA1. Link, Google Scholar 31 : The influence of finasteride on the development of prostate cancer. N Engl J Med2003; 349: 215. Google Scholar 32 : Prostate cancer and the Will Rogers phenomenon. J Natl Cancer Inst2005; 97: 1248. Google Scholar 33 : Estimation of treatment benefits when PSA screening for prostate cancer is discontinued at different ages. Urology2005; 66: 1038. Google Scholar 34 Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med2008; 149: 185. Google Scholar 35 : Pathological characteristics of prostate cancer detected through prostate specific antigen based screening. J Urol2006; 175: 902. Link, Google Scholar 36 : Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol2004; 172: 910. Link, Google Scholar 37 : Are pelvic computed tomography, bone scan, and pelvic lymphadenectomy necessary in the staging of prostatic cancer?. Br J Urol1995; 75: 778. Google Scholar 38 : The prostatic specific antigen era is alive and well: prostatic specific antigen and biochemical progression following radical prostatectomy. J Urol2005; 174: 1276. Link, Google Scholar 39 : Baseline staging of newly diagnosed prostate cancer: a summary of the literature. J Urol2004; 171: 2122. Link, Google Scholar 40 : The role of lymphadenectomy in prostate cancer. Nat Clin Pract Urol2005; 2: 336. Google Scholar 41 : Adjuvant radiotherapy for patients with locally advanced prostate cancer – a new standard?. Eur Urol2008; 54: 528. Google Scholar 42 : Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association prostate guidelines for localized prostate cancer update panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol2007; 177: 540. Link, Google Scholar 43 : Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol2006; 24: 3973. Google Scholar 44 : Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys2007; 67: 327. Google Scholar 45 : Definitions of biochemical failure that best predict clinical failure in patients with prostate cancer treated with external beam radiation alone: a multi-institutional pooled analysis. J Urol2005; 173: 797. Link, Google Scholar 46 : PSA kinetics provide improved prediction of survival in metastatic hormone-refractory prostate cancer. Urology2008; 72: 903. Google Scholar 47 : Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure. J Clin Oncol2005; 23: 6556. Google Scholar 48 : Prostate cancer-specific survival following salvage radiotherapy vs. observation in men with biochemical recurrence after radical prostatectomy. JAMA2008; 299: 2760. Google Scholar 49 : Salvage radical prostatectomy: quality of life outcomes and long-term oncological control of radiorecurrent prostate cancer. J Urol2006; 176: 2025. Link, Google Scholar 50 : Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA2005; 294: 433. Google Scholar 51 : Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst2003; 95: 1376. Google Scholar American Urological Association Education and Research, Inc., Linthicum, Maryland© 2009 by American Urological AssociationFiguresReferencesRelatedDetailsCited bySammon J, Dalela D, Abdollah F, Choueiri T, Han P, Hansen M, Nguyen P, Sood A, Menon M and Trinh Q (2015) Determinants of Prostate Specific Antigen Screening among Black Men in the United States in the Contemporary EraJournal of Urology, VOL. 195, NO. 4 Part 1, (913-918), Online publication date: 1-Apr-2016.Ross I, Womble P, Ye J, Linsell S, Montie J, Miller D and Cher M (2014) MUSIC: Patterns of Care in the Radiographic Staging of Men with Newly Diagnosed Low Risk Prostate CancerJournal of Urology, VOL. 193, NO. 4, (1159-1162), Online publication date: 1-Apr-2015.Dorin R, Finnegan K, Staff I and Wagner J (2014) Was a Change to a Urologist Owned Pathology Laboratory Associated with a Change in Prostate Biopsy Use?Urology Practice, VOL. 1, NO. 2, (62-66), Online publication date: 1-Jul-2014.Aslani A, Minnillo B, Johnson B, Cherullo E, Ponsky L and Abouassaly R (2013) The Impact of Recent Screening Recommendations on Prostate Cancer Screening in a Large Health Care SystemJournal of Urology, VOL. 191, NO. 6, (1737-1742), Online publication date: 1-Jun-2014.Patel H, Feng Z, Landis P, Trock B, Epstein J and Carter H (2013) Prostate Specific Antigen Velocity Risk Count Predicts Biopsy Reclassification for Men with Very Low Risk Prostate CancerJournal of Urology, VOL. 191, NO. 3, (629-637), Online publication date: 1-Mar-2014.Jeong I, Lim J, You D, Kim M, Choi H, Kim J, Cho K, Hong J, Ahn H and Kim C (2013) Incremental Value of Magnetic Resonance Imaging for Clinically High Risk Prostate Cancer in 922 Radical ProstatectomiesJournal of Urology, VOL. 190, NO. 6, (2054-2060), Online publication date: 1-Dec-2013.Belsante M, Zhao L, Hudak S, Lotan Y and Morey A (2013) Cost-Effectiveness of Risk Stratified Followup after Urethral Reconstruction: A Decision AnalysisJournal of Urology, VOL. 190, NO. 4, (1292-1297), Online publication date: 1-Oct-2013.Helfand B, Loeb S, Hu Q, Cooper P, Roehl K, McGuire B, Baumann N and Catalona W (2012) Personalized Prostate Specific Antigen Testing Using Genetic Variants May Reduce Unnecessary Prostate BiopsiesJournal of Urology, VOL. 189, NO. 5, (1697-1701), Online publication date: 1-May-2013.Hilton J, Blaschko S, Whitson J, Cowan J and Carroll P (2012) The Impact of Serial Prostate Biopsies on Sexual Function in Men on Active Surveillance for Prostate CancerJournal of Urology, VOL. 188, NO. 4, (1252-1259), Online publication date: 1-Oct-2012.Li J, Thompson T, Joseph D and Master V (2012) Association Between Smoking Status, and Free, Total and Percent Free Prostate Specific AntigenJournal of Urology, VOL. 187, NO. 4, (1228-1233), Online publication date: 1-Apr-2012.Borin J (2011) Imaging for Staging Prostate Cancer—Too Much or Not Enough?Journal of Urology, VOL. 186, NO. 3, (779-780), Online publication date: 1-Sep-2011.Miller D, Murtagh D, Suh R, Knapp P, Schuster T, Dunn R and Montie J (2011) Regional Collaboration to Improve Radiographic Staging Practices Among Men With Early Stage Prostate CancerJournal of Urology, VOL. 186, NO. 3, (844-849), Online publication date: 1-Sep-2011.Loeb S and Sandhu J (2011) Use of Empiric Antibiotics in the Setting of an Increased Prostate Specific AntigenJournal of Urology, VOL. 186, NO. 1, (17-19), Online publication date: 1-Jul-2011.Brassell S, Rice K, Parker P, Chen Y, Farrell J, Cullen J and McLeod D (2010) Prostate Cancer in Men 70 Years Old or Older, Indolent or Aggressive: Clinicopathological Analysis and OutcomesJournal of Urology, VOL. 185, NO. 1, (132-137), Online publication date: 1-Jan-2011. (2010) Reply by AuthorsJournal of Urology, VOL. 184, NO. 4, (1572-1573), Online publication date: 1-Oct-2010.Related articlesJournal of Urology10 Nov 2018Prostate Specific Antigen Best Practice Statement: 2009 Update Volume 182Issue 5November 2009Page: 2232-2241 Advertisement Copyright & Permissions© 2009 by American Urological AssociationKeywordsprostate-specific antigenprostatic neoplasmsmass screeningneoplasm stagingtreatment outcomeMetricsAuthor Information Kirsten L. Greene Financial and/or other relationship with Takeda. More articles by this author Peter C. Albertsen Financial and/or other relationship with Blue Cross/Blue Shield, GlaxoSmithKline, National Cancer Institute, Agency Health Care Quality, Aureon Corportion, Sanofi, Ikonysis. More articles by this author Richard J. Babaian Financial and/or other relationship with Endocare, Gen-Probe. More articles by this author H. Ballentine Carter More articles by this author Peter H. Gann More articles by this author Misop Han More articles by this author Deborah Ann Kuban Financial and/or other relationship with Calypso Medical. More articles by this author A. Oliver Sartor Financial and/or other relationship with AstraZeneca, Sanofi-Aventis, GlaxoSmithKline. More articles by this author Janet L. Stanford More articles by this author Anthony Zietman Financial and/or other relationship with Ismar Medical, Ismar Healthcare. More articles by this author Peter Carroll Financial and/or other relationship with National Cancer Institute, AstraZeneca, Takeda. More articles by this author Expand All Advertisement PDF downloadLoading ...
